Luzitin’s Redaporfin treatment (LUZ11) is a novel combination therapy which is applicable to virtually all solid tumors accessible to minimally invasive illumination with its optical fibre laser light source.
Luzitin S.A. is one of the Portuguese start-ups which Blueclinical helped going from bench to clinical trials. The trial is currently ongoing and the first group of patients has just finished its participation in Phase I/II clinical trial in advanced head and neck cancer.
Blueclinical contributed to this project since the scientific advice request to protocol development and approval. This trial will go down in the history of Portuguese clinical pharmacology as the first "entry-into-Man" trial of an oncology product held in Portugal. Blueclinical has also contributed to the application to EMA that granted LUZ11 the orphan drug designation for cholangiocarcinoma.
This clinical trial was implemented in Hospital CUF Porto and IPO do Porto. Professor Lucio Lara-Santos is the principal investigator for LUZ11 Phase I/II clinical trial.If you would like to know more about this Clinical Trial please visit the website